- Posted by Minos Matsoukas
- On 13/09/2018
Kritsi E, Matsoukas MT, Potamitis C, Karageorgos V, Detsi A, Magafa V, Liapakis G, Mavromoustakos T, Zoumpoulakis P.
In this study, Cloudpharm participated in a study for the discovery of novel agents bearing different scaffolds which may evolve as a new class of AT1 receptor antagonists. Nowadays, AT1 receptor (AT1R) antagonists (ARBs) constitute the one of the most prevalent classes of antihypertensive drugs that modulate the renin-angiotensin system (RAS). Towards this direction, this study resulted in the identification of four compounds with completely diverse chemical scaffolds from other ARBs, with high nanomolar to micromolar affinity.